Venglustat - Sanofi Genzyme

Drug Profile

Venglustat - Sanofi Genzyme

Alternative Names: Genz-682452-AA; GZ-402671; GZ/SAR402671; Ibiglustat; SAR-402671

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Azabicyclo compounds; Carbamates; Small molecules; Thiazoles
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Polycystic kidney disease
  • Phase II Fabry's disease; Gaucher's disease; Parkinson's disease

Most Recent Events

  • 31 Jul 2018 Sanofi announces its intention to submit regulatory application for Gaucher's disease in 2022
  • 31 Jul 2018 Sanofi announces its intention to submit regulatory application for Polycystic kidney disease in 2021
  • 31 Jul 2018 Sanofi announces its intention to submit regulatory application for Fabry's disease in 2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top